At Sanofi Genzyme, we realize that we don't always have all the answers to the medical challenges we seek to address – and recognize that working with others can often lead to the best solutions. Over the years, collaboration has helped us advance many goals: Exploring how an established cancer treatment might help multiple sclerosis patients. Establishing clinical trials instrumental to getting a critical enzyme replacement therapy approved. Gaining insights into the marketability of gene therapy. And those are just a few examples.
We're comfortable working with external collaborators and integrating others' efforts with our own, because that's been our approach from day one. The history and evolution of our company is defined by strategic partnerships, mergers, acquisitions, and licensing that have expanded Sanofi Genzyme's scientific expertise and contributed to our product portfolio. We're always open to exploring innovative ideas – at all stages of development – that we can help to move forward.
Partnership with Alnylam
We recently entered into a partnership with Alnylam Pharmaceuticals to co-develop and co-commercialize several potential treatments for rare genetic diseases. These products are a new class of therapeutics based on RNA interference. RNAi, also known as “gene silencing,” works by inhibiting the production of proteins that cause or contribute to the targeted disease.
Last Updated: 6/28/2016